RiverPark Advisors’s Drugs Made In America Acquisition Corp DMAA Stock Holding History
Bought
Maintained
Sold
Other funds holding DMAA
RiverPark Advisors's DMAA Position: Q3 2026 in Review
RiverPark Advisors opened a new position in Drugs Made In America Acquisition Corp (DMAA) in Q3 2026: 264,866 shares worth $2.88M. The stake represents 1.25% of the portfolio and ranks #25 among its holdings.
23 funds tracked by Wall St. Rank hold DMAA as of Q3 2026.
- RiverPark Advisors held 264,866 shares of Drugs Made In America Acquisition Corp worth $2.88M as of Q3 2026.
- Drugs Made In America Acquisition Corp was a new RiverPark Advisors position in Q3 2026.
- Drugs Made In America Acquisition Corp made up 1.25% of RiverPark Advisors's portfolio in Q3 2026, its #25 holding.
- 23 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q3 2026.
Based on RiverPark Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.